論文使用權限 Thesis access permission:自定論文開放時間 user define
開放時間 Available:
校內 Campus:永不公開 not available
校外 Off-campus:永不公開 not available
論文名稱 Title |
探討BCL6基因在膀胱尿路上皮癌細胞株中影響Cisplatin敏感性反應變化及其分子機制 Studies the effect of BCL6 gene on the sensitivity of Cisplatin in bladder urothelial carcinoma cell lines |
||
系所名稱 Department |
|||
畢業學年期 Year, semester |
語文別 Language |
||
學位類別 Degree |
頁數 Number of pages |
57 |
|
研究生 Author |
|||
指導教授 Advisor |
|||
召集委員 Convenor |
|||
口試委員 Advisory Committee |
|||
口試日期 Date of Exam |
2017-08-28 |
繳交日期 Date of Submission |
2017-09-13 |
關鍵字 Keywords |
抗藥性、細胞凋亡、CDC42、B-cell lymphoma 6 protein (BCL6)、膀胱癌、TP53、順鉑 Bladder cancer, TP53, B-cell lymphoma 6 protein (BCL6), Apoptosis, Drug resistance, Cisplatin, CDC42 |
||
統計 Statistics |
本論文已被瀏覽 5651 次,被下載 0 次 The thesis/dissertation has been browsed 5651 times, has been downloaded 0 times. |
中文摘要 |
Cisplatin 是化療的重要用藥,對於膀胱癌,小細胞肺癌及卵巢癌均有良好的治療效果。不過有部分泌尿上皮癌病患使用Cisplatin治療一段時間後會產生耐藥性,進而影響治療效果。為此,了解泌尿上皮癌細胞對於Cisplatin耐藥性的作用機轉是相當重要的。而B-cell lymphoma 6 protein (BCL6),是一種transcription repressor,會與transcription factor交互作用,而抑制細胞核的轉錄作用,並會抑制DNA repair及TP53的活性。本篇研究中使用人類膀胱癌細胞株 (BFTC905、T24),並以遞增Cisplatin濃度的方式,篩選出具有Cisplatin耐藥性的T24 (T24R1、T24R2)。我們想藉由比較上述幾個細胞株,在BCL6 gene 及其可能參與的相關路徑下游基因之mRNA及Protein level上的差異,進而探討造成耐藥性的相關作用機制。 |
Abstract |
Cisplatin is one of the most effective anticancer drugs used for treatment of tumors, including bladder, small cell lung and ovarian cancers. During the cisplatin treatment of urothelial cancer, some patients will become to be cisplatin resistance, and then it will influence the outcome of treatment. Therefore, it is an important topic how to characterize the cisplatin-resistant mechanism in human urinary bladder urothelial carcinoma (UBUC) cells. B-cell lymphoma 6 protein is transcription repressor and interaction with transcription factor, regulates gene expression. BCL6 is proto-oncogene and it inhibit DNA repair pathways and TP53 protein. According to the report, we find that the BCL6 overexpression in many cancer cell. Our use the array comparative genomic hybridization, explore the BCL6 overexpression in bladder cancer cell. Thus, we suspect that BCL6 have the important role in bladder cancer. To evaluate the BCL6 gene in urinary bladder urothelial carcinoma-derived cell lines would sensitize their responses to cisplatin and study the underlying molecular mechanisms. |
目次 Table of Contents |
論文審定書………………………………………………………………..i 致謝 ………………………………………………………………………ii 中文摘要 …………………………………………………………………iii 英文摘要 …………………………………………………………………iv 英文縮寫表 ………………………………………………...……….……v 目錄 ………………………………………………………………………vi 圖次 …………………………………………………………………...…vii 表次 ……………………………………………………………….…….viii 壹、 緒論 (Introduction) …………………………………………………1 貳、 實驗材料與方法 (Materials and methods)……………….……..10 參、 結果 (Results)……………………………………………………...28 肆、 討論 (Discussion) …………………………………………………41 伍、 參考文獻 (References) …………………………………...………42 |
參考文獻 References |
Aebi, S., B. Kurdi-Haidar, R. Gordon, B. Cenni, H. Zheng, D. Fink, R. D. Christen, C. R. Boland, M. Koi, R. Fishel, and S. B. Howell. 1996. Loss of DNA Mismatch Repair in Acquired Resistance to Cisplatin. Cancer research 56(13):3087-3090. Agarwal, R., and S. B. Kaye. 2003. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3(7):502-516. (10.1038/nrc1123) doi: http://www.nature.com/nrc/journal/v3/n7/suppinfo/nrc1123_S1.html Aldousari, S., and W. Kassouf. 2010. Update on the management of non-muscle invasive bladder cancer. Canadian Urological Association Journal 4(1):56-64. Alina, K., U. Kazuo, and B. Benjamin. 2009. Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-&#954;B Inhibitor DHMEQ. Current Pharmaceutical Design 15(7):792-808. doi: http://dx.doi.org/10.2174/138161209787582156 Antoni, S., J. Ferlay, I. Soerjomataram, A. Znaor, A. Jemal, and F. Bray. 2016. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology 71(1):96-108. doi: 10.1016/j.eururo.2016.06.010 Basu, A., and S. Krishnamurthy. 2010. Cellular Responses to Cisplatin-Induced DNA Damage. Bert, V., S. Surojit, and P. Carol. 2010. p53 - The most frequently altered gene in human cancers. Nature Education at Scitable 3(9):6. Blick, C., P. Hall, T. Pwint, F. Al-Terkait, J. Crew, T. Powles, V. Macaulay, N. Munro, D. Douglas, N. Kilbey, A. Protheroe, and J. D. Chester. 2012. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer 118(16):3920-3927. doi: 10.1002/cncr.26675 Bonavida, B. 2014. RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-&#954;B/Snail/YY1/RKIP Resistance-Driver Loop. 19(6):431-445. doi: 10.1615/CritRevOncog.2014011929 Bubenik, J., M. Baresova, V. Viklicky, J. Jakoubkova, H. Sainerova, and J. Donner. 1973. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. International journal of cancer 11(3):765-773. Byun, S.-S., S. W. Kim, H. Choi, C. Lee, and E. Lee. 2005. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU International 95(7):1086-1090. doi: 10.1111/j.1464-410X.2005.05472.x Cao, D., R. T. Vollmer, J. Luly, S. Jain, T. M. Roytman, C. W. Ferris, and M. L. A. Hudson. 2010. Comparison of 2004 and 1973 World Health Organization Grading Systems and Their Relationship to Pathologic Staging for Predicting Long-term Prognosis in Patients With Urothelial Carcinoma. Urology 76(3):593-599. doi: http://dx.doi.org/10.1016/j.urology.2010.01.032 Catto, J. W. F., G. Xinarianos, J. L. Burton, M. Meuth, and F. C. Hamdy. 2003. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. International journal of cancer 105(4):484-490. doi: 10.1002/ijc.11109 Chen, Z., J. Yang, G. Wang, B. Song, J. Li, and Z. Xu. 2007. Attenuated Expression of Xeroderma Pigmentosum Group C Is Associated with Critical Events in Human Bladder Cancer Carcinogenesis and Progression. Cancer research 67(10):4578-4585. doi: 10.1158/0008-5472.can-06-0877 Cheng, Y. T., Y. L. Li, J. D. Wu, S. B. Long, T. S. Tzai, C. C. Tzeng, and M. D. Lai. 1995. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines. Molecular carcinogenesis 13(3):173-181. Chung, J., C. Kwak, R. J. Jin, C.-H. Lee, K. H. Lee, and S. E. Lee. 2004. Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Letters 203(2):155-161. doi: http://dx.doi.org/10.1016/j.canlet.2003.07.008 Cohen, S. M., and S. J. Lippard. 2001. Cisplatin: From DNA damage to cancer chemotherapy. Progress in Nucleic Acid Research and Molecular Biology 67:93-130. doi: http://dx.doi.org/10.1016/S0079-6603(01)67026-0 Cooper, M. J., J. J. Haluschak, D. Johnson, S. Schwartz, L. J. Morrison, M. Lippa, G. Hatzivassiliou, and J. Tan. 1994. p53 mutations in bladder carcinoma cell lines. Oncology research 6(12):569-579. Dasari, S., and P. B. Tchounwou. 2014. Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology 0:364-378. doi: 10.1016/j.ejphar.2014.07.025 Endo, M., M. A. Antonyak, and R. A. Cerione. 2009. Cdc42-mTOR Signaling Pathway Controls Hes5 and Pax6 Expression in Retinoic Acid-dependent Neural Differentiation(). The Journal of Biological Chemistry 284(8):5107-5118. doi: 10.1074/jbc.M807745200 Florea, A.-M., and D. Büsselberg. 2011. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers 3(1):1351-1371. doi: 10.3390/cancers3011351 Gaikwad, S. M., B. Thakur, A. Sakpal, R. K. Singh, and P. Ray. 2015. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. The International Journal of Biochemistry & Cell Biology 61:90-102. doi: http://dx.doi.org/10.1016/j.biocel.2015.02.001 Galluzzi, L., L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M. Castedo, and G. Kroemer. 2012. Molecular mechanisms of cisplatin resistance. Oncogene 31(15):1869-1883. Hall, A. R., B. R. Dix, S. J. O'Carroll, and A. W. Braithwaite. 1998. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 4(9):1068-1072. (10.1038/2057) Hatzi, K., and A. Melnick. 2014. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends in Molecular Medicine 20(6):343-352. doi: 10.1016/j.molmed.2014.03.001 Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296-299. doi: 10.1038/387296a0 Hoffman-Censits, J. H., E. J. Trabulsi, D. Y. T. Chen, A. Kutikov, J. Lin, R. Viterbo, G. R. Hudes, K. A. Healy, S. Hubosky, Y.-N. Wong, D. Kilpatrick, B. Adair, C. Cione, and E. R. Plimack. 2014. Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma. Journal of Clinical Oncology 32(4_suppl):326-326. doi: 10.1200/jco.2014.32.4_suppl.326 Hsieh, J. L., C. L. Wu, C. H. Lee, and A. L. Shiau. 2003. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clinical cancer research : an official journal of the American Association for Cancer Research 9(1):338-345. Isonishi, S., P. A. Andrews, and S. B. Howell. 1990. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem 265(7):3623-3627. Ito, Y., E. Kikuchi, N. Tanaka, T. Kosaka, E. Suzuki, R. Mizuno, T. Shinojima, A. Miyajima, K. Umezawa, and M. Oya. 2015. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer. BMC Cancer 15:324. doi: 10.1186/s12885-015-1315-9 Jacobs, B. L., C. T. Lee, and J. E. Montie. 2010. Bladder Cancer in 2010: How Far have We Come? CA: A Cancer Journal for Clinicians 60(4):244-272. doi: 10.3322/caac.20077 Jardin, F., P. Ruminy, C. Bastard, and H. Tilly. 2007a. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathologie-biologie 55(1):73-83. doi: 10.1016/j.patbio.2006.04.001 Jardin, F., P. Ruminy, C. Bastard, and H. Tilly. 2007b. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathologie Biologie 55(1):73-83. doi: http://dx.doi.org/10.1016/j.patbio.2006.04.001 Katsman, A., K. Umezawa, and B. Bonavida. 2007. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resistance Updates 10(1):1-12. doi: http://dx.doi.org/10.1016/j.drup.2007.01.002 Kelland, L. 2007. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573-584. (10.1038/nrc2167) Kruiswijk, F., C. F. Labuschagne, and K. H. Vousden. 2015. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 16(7):393-405. (Review) doi: 10.1038/nrm4007 Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387(6630):299-303. doi: 10.1038/387299a0 Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88(3):323-331. Maase, H. v. d., S. W. Hansen, J. T. Roberts, L. Dogliotti, T. Oliver, M. J. Moore, I. Bodrogi, P. Albers, A. Knuth, C. M. Lippert, P. Kerbrat, P. S. Rovira, P. Wersall, S. P. Cleall, D. F. Roychowdhury, I. Tomlin, C. M. Visseren-Grul, and P. F. Conte. 2000. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. Journal of Clinical Oncology 18(17):3068-3077. doi: 10.1200/jco.2000.18.17.3068 Markl, I. D., and P. A. Jones. 1998. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer research 58(23):5348-5353. Martin, L. P., T. C. Hamilton, and R. J. Schilder. 2008. Platinum Resistance: The Role of DNA Repair Pathways. Clinical Cancer Research 14(5):1291-1295. doi: 10.1158/1078-0432.ccr-07-2238 Martinez, V. D., E. A. Vucic, D. D. Becker-Santos, L. Gil, and W. L. Lam. 2011. Arsenic Exposure and the Induction of Human Cancers. Journal of Toxicology 2011:431287. doi: 10.1155/2011/431287 Melendez, J., M. Grogg, and Y. Zheng. 2011. Signaling Role of Cdc42 in Regulating Mammalian Physiology. The Journal of Biological Chemistry 286(4):2375-2381. doi: 10.1074/jbc.R110.200329 O'Toole, C., Z. H. Price, Y. Ohnuki, and B. Unsgaard. 1978. Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. British Journal of Cancer 38(1):64-76. Okada, T., K. Murata, R. Hirose, C. Matsuda, T. Komatsu, M. Ikekita, M. Nakawatari, F. Nakayama, M. Wakatsuki, T. Ohno, S. Kato, T. Imai, and T. Imamura. 2013. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells. 3:2899. (Article) doi: 10.1038/srep02899 https://www.nature.com/articles/srep02899#supplementary-information Osmani, N., F. Peglion, P. Chavrier, and S. Etienne-Manneville. 2010. Cdc42 localization and cell polarity depend on membrane traffic. The Journal of Cell Biology 191(7):1261-1269. doi: 10.1083/jcb.201003091 Osmani, N., N. Vitale, J.-P. Borg, and S. Etienne-Manneville. 2006. Scrib Controls Cdc42 Localization and Activity to Promote Cell Polarization during Astrocyte Migration. Current Biology 16(24):2395-2405. doi: http://dx.doi.org/10.1016/j.cub.2006.10.026 Perego, P., M. Giarola, S. C. Righetti, R. Supino, C. Caserini, D. Delia, M. A. Pierotti, T. Miyashita, J. C. Reed, and F. Zunino. 1996. Association between Cisplatin Resistance and Mutation of <em>p53</em> Gene and Reduced Bax Expression in Ovarian Carcinoma Cell Systems. Cancer research 56(3):556-562. Phan, R. T., and R. Dalla-Favera. 2004. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432(7017):635-639. (10.1038/nature03147) doi: http://www.nature.com/nature/journal/v432/n7017/suppinfo/nature03147_S1.html Plimack, E. R., J. H. Hoffman-Censits, R. Viterbo, R. E. Greenberg, D. Chen, C. D. Lallas, E. J. Trabulsi, Y.-N. Wong, A. Kutikov, J. Lin, G. Duncan, B. Adair, C. Cione, C. O'Sullivan, D. Kilpatrick, E. A. Ross, S. A. Boorjian, R. G. Uzzo, W. K. Kelly, and G. R. Hudes. 2012. Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study. Journal of Clinical Oncology 30(15_suppl):4526-4526. doi: 10.1200/jco.2012.30.15_suppl.4526 Plimack, E. R., J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes. 2014. Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology 32(18):1895-1901. doi: 10.1200/jco.2013.53.2465 Rieger, K. M., A. F. Little, J. M. Swart, W. V. Kastrinakis, J. M. Fitzgerald, D. T. Hess, J. A. Libertino, and I. C. Summerhayes. 1995. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. British Journal of Cancer 72(3):683-690. Sengupta, S., and C. C. Harris. 2005. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6(1):44-55. (10.1038/nrm1546) Sherr, C. J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes & development 12(19):2984-2991. Siegel, R. L., K. D. Miller, and A. Jemal. 2016. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians 66(1):7-30. doi: 10.3322/caac.21332 Sinha, S., and W. Yang. 2008. Cellular signaling for activation of Rho GTPase Cdc42. Cellular Signalling 20(11):1927-1934. doi: http://dx.doi.org/10.1016/j.cellsig.2008.05.002 Takashi Kumagai1, T. M., Mika Kikuchi2, Tetsuya Fukuda1, Nobuyuki Miyasaka1, Ryuichi Kamiyama2 and Shinsaku Hirosawa1,a. 1999a. The proto-oncogene Bcl6 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene 18(2):467-475. Takashi Kumagai1, T. M., Mika Kikuchi2, Tetsuya Fukuda1, Nobuyuki Miyasaka1, Ryuichi Kamiyama2 and Shinsaku Hirosawa1,a. 1999b. The proto-oncogene Bcl6 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene 18:467-475. Tang, Y., A. R. Simoneau, J. Xie, B. Shahandeh, and X. Zi. 2008. Effects of the Kava Chalcone Flavokawain A Differ in Bladder Cancer Cells with Wild-type versus Mutant p53. Cancer prevention research (Philadelphia, Pa.) 1(6):439-451. doi: 10.1158/1940-6207.CAPR-08-0165 Tzeng, C. C., H. S. Liu, C. Li, Y. T. Jin, R. M. Chen, W. H. Yang, and J. S. Lin. 1996. Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer research 16(4a):1797-1804. Walker, S. R., S. Liu, M. Xiang, M. Nicolais, K. Hatzi, E. Giannopoulou, O. Elemento, L. Cerchietti, A. Melnick, and D. A. Frank. 2015. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene 34(9):1073-1082. (Original Article) doi: 10.1038/onc.2014.61 Wang, G., L. Chuang, X. Zhang, S. Colton, A. Dombkowski, J. Reiners, A. Diakiw, and X. S. Xu. 2004. The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation. Nucleic Acids Research 32(7):2231-2240. doi: 10.1093/nar/gkh541 Wang, J., and G. S. Wu. 2014. Role of autophagy in cisplatin resistance in ovarian cancer cells. Journal of Biological Chemistry doi: 10.1074/jbc.M114.558288 Witjes, J. A., M. Wullink, G. O. Oosterhof, and P. de Mulder. 1997. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol 31(4):414-419. Woods, D. B., and K. H. Vousden. 2001. Regulation of p53 function. Experimental cell research 264(1):56-66. doi: 10.1006/excr.2000.5141 Wu, Q., X. Liu, H. Yan, Y.-h. He, S. Ye, X.-w. Cheng, G.-l. Zhu, W.-y. Wu, X.-n. Wang, X.-j. Kong, X.-c. Xu, P. E. Lobie, T. Zhu, and Z.-s. Wu. 2014. B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells. BMC Cancer 14(1):418. (journal article) doi: 10.1186/1471-2407-14-418 Zamble, D. B., T. Jacks, and S. J. Lippard. 1998. p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 95(11):6163-6168. |
電子全文 Fulltext |
本電子全文僅授權使用者為學術研究之目的,進行個人非營利性質之檢索、閱讀、列印。請遵守中華民國著作權法之相關規定,切勿任意重製、散佈、改作、轉貼、播送,以免觸法。 論文使用權限 Thesis access permission:自定論文開放時間 user define 開放時間 Available: 校內 Campus:永不公開 not available 校外 Off-campus:永不公開 not available 您的 IP(校外) 位址是 54.208.135.174 論文開放下載的時間是 校外不公開 Your IP address is 54.208.135.174 This thesis will be available to you on Indicate off-campus access is not available. |
紙本論文 Printed copies |
紙本論文的公開資訊在102學年度以後相對較為完整。如果需要查詢101學年度以前的紙本論文公開資訊,請聯繫圖資處紙本論文服務櫃台。如有不便之處敬請見諒。 開放時間 available 永不公開 not available |
QR Code |